Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists
Sadiya S. Khan, Chiadi E. Ndumele, Dhruv S. Kazi
Abstract
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.
Topics & Concepts
MedicineDiscontinuationGlucagon-like peptide-1ReceptorGlucagon-like peptide 1 receptorEquity (law)Internal medicinePharmacologyEndocrinologyAgonistDiabetes mellitusType 2 diabetesLawPolitical scienceDiabetes Treatment and ManagementNeuroendocrine Tumor Research AdvancesPharmaceutical studies and practices